These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38553292)

  • 1. Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.
    Grant LR; Hanquet G; Sepúlveda-Pachón IT; Theilacker C; Baay M; Slack MPE; Jodar L; Gessner BD
    Vaccine; 2024 Apr; 42(12):2983-2993. PubMed ID: 38553292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
    Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.
    Naucler P; Galanis I; Morfeldt E; Darenberg J; Örtqvist Å; Henriques-Normark B
    Clin Infect Dis; 2017 Nov; 65(11):1780-1789. PubMed ID: 29020171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
    Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L
    Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: A systematic literature review.
    Reyburn R; Maher J; von Mollendorf C; Gwee A; Mulholland K; Russell F;
    J Glob Health; 2023 Feb; 13():05001. PubMed ID: 36799235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of Streptococcus pneumoniae serogroup 6 isolates from IPD in children and adults in Germany.
    van der Linden M; Winkel N; Küntzel S; Farkas A; Perniciaro SR; Reinert RR; Imöhl M
    PLoS One; 2013; 8(4):e60848. PubMed ID: 23593324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
    Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L
    Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
    Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
    Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
    Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of pneumococcal conjugate vaccines on serotype 19A nasopharyngeal carriage.
    Tin Tin Htar M; Sings HL; Syrochkina M; Taysi B; Hilton B; Schmitt HJ; Gessner BD; Jodar L
    Expert Rev Vaccines; 2019 Dec; 18(12):1243-1270. PubMed ID: 31587592
    [No Abstract]   [Full Text] [Related]  

  • 13. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal expansion of the macrolide resistant ST386 within pneumococcal serotype 6C in France.
    Janoir C; Cohen R; Levy C; Bingen E; Lepoutre A; Gutmann L; Varon E;
    PLoS One; 2014; 9(3):e90935. PubMed ID: 24603763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
    Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
    Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium.
    Wouters I; Desmet S; Van Heirstraeten L; Blaizot S; Verhaegen J; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2019 Feb; 37(8):1080-1086. PubMed ID: 30665775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines.
    Hadjipanayis A; Efstathiou E; Alexandrou M; Panayiotou L; Zachariadou C; Petrou P; Papaevangelou V
    PLoS One; 2016; 11(10):e0163269. PubMed ID: 27706247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population structure of Streptococcus pneumoniae colonizing children before and after universal use of pneumococcal conjugate vaccines in Brazil: emergence and expansion of the MDR serotype 6C-CC386 lineage.
    Neves FPG; Cardoso NT; Souza ARV; Snyder RE; Marlow MM; Pinto TCA; Teixeira LM; Riley LW
    J Antimicrob Chemother; 2018 May; 73(5):1206-1212. PubMed ID: 29401243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
    Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
    Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.